TSX Exchange Symbol: RVX
CALGARY, Aug. 15, 2014 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has closed the previously-announced amendments which provided for the loan granted to Resverlogix by Citibank, N.A. to be increased by $30 million to $68.8 million, as more particularly described in the management information circular dated July 14, 2014.
Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company developing compounds involving a therapeutic increase in ApoA-I. Resverlogix's RVX-208 is a first-in-class small molecule for the treatment of atherosclerosis and other chronic diseases such as Diabetes Mellitus and Alzheimer's disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog.
Donald J. McCaffrey
President and CEO
SOURCE Resverlogix Corp.